Table 1

Data collected at study visit

Study periodScreeningEnrolment
baseline
InterventionFollow-up
Weeks−2021624
Informed consentX
Serum antitransglutaminaseX
Eligibility criteriaX
RandomisationX
Assessments
Sociodemographic characteristicsX
Medical historyX
Concomitant medications*XXX
Physical examinationXXX
X-ray of the pelvis (if not available)X
Primary outcome: Quality of life (ASAS-HI)XXX
Patient-reported outcome†XXX
Dietician consultationXXXX
Laboratory samplesXX
Faecal samples: gut microbiota analysisXX
  • *Including disease modifying antirheumatic drugs, non-steroidal anti-inflammatory drug, painkillers, corticoids.

  • †Including Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Hospital Anxiety and Depression Scale, Fibromyalgia Rapid Screening Tool, Functional Assessment of Chronic Illness Therapy and a digestive discomfort questionnaire.

  • ASAS-HI, Assessment of SpondyloArthritis International Society—Health Index.